September 20, 2023
Dabrafenib plus Trametinib in Pediatric Glioma with BRAF V600 Mutations
Key Points
Key points are not available for this paper at this time.
Abstract
Among pediatric patients with low-grade glioma with BRAF V600 mutations, dabrafenib plus trametinib resulted in significantly more responses, longer progression-free survival, and a better safety profile than standard chemotherapy as first-line therapy. (Funded by Novartis; ClinicalTrials.gov number, NCT02684058.).
Connected Papers
Building similarity graph...
Analyzing shared references across papers
Discussion
Loading...
Authors
Éric Bouffet
Université Paris-Sud
J
Jordan R. Hansford
South Australia Pathology
M
Maria Luisa Garrè
Istituto Giannina Gaslini
Journals
New England Journal of Medicine
Actions
Institutions
University of Toronto
University College London
Heidelberg University
References and Citations
Connected Papers
Building similarity graph...
Analyzing shared references across papers
Discussion
Loading...